News & Events

Clinigen Group Extends Exclusive Foscavir® US Distribution Agreement with Hospira to 2019

Clinigen Group Extends Exclusive Foscavir® US Distribution Agreement with Hospira to 2019

Burton on Trent, UK – 11 March 2015 – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN) today announces the extension and renegotiation of the exclusive license and distribution agreement with Hospira, Inc (‘Hospira’) for its anti-viral product Foscavir® (foscarnet sodium) in the US.  This is expected to be beneficial to both parties.

The original distribution agreement with Hospira established in July 2011 was due to expire in May 2017. The new agreement is for five years extending the term to 31 December 2019.

Foscavir® is Clinigen’s lead product.  Foscavir® received FDA approval in May 2012 for the treatment of HIV/AIDS-related cytomegalovirus infections and herpes. In September 2014, the FDA recognized the determined efforts made by Clinigen in providing Foscavir® to patients in the US by awarding Clinigen the first Drug Shortage Assistance Award.

Peter George, Chief Executive Officer, Clinigen Group said: “Hospira has been an excellent partner in the US, working closely with Clinigen since we acquired Foscavir®. The new five year agreement recognizes the strength of this partnership and shows the commitment of both Hospira and Clinigen to the continued supply of Foscavir® to US patients.”

About Foscavir®
Foscavir® (foscarnet sodium) is an anti-viral licensed to treat cytomegalovirus (CMV) retinitis in HIV patients and for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients.

About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering ‘the right drug, to the right patient at the right time’, has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP is focused on acquiring its own intellectual property in licensed, niche, hospital-only critical care medicines, increasing the value of these medicines by developing new formulations and indications, then registering and marketing them in defined global markets.

For more information, please visit

Issued for and on behalf of Clinigen Group by Instinctif Partners.

For more information please contact​

back to news


Melanie Toyne-SewellManaging Partner